Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Other Non Operating Income of -$55000.0 for Q1 2026, down 131.79% year-over-year from $173000.0 in Q1 2025, and down 10.0% quarter-over-quarter from -$50000.0 in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$55000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 131.79% year-over-year to -$55000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 140.48% YoY), while the FY2025 annual figure was $1.5 million, up 155.87% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$55000.0, down from -$50000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $1.4 million in Q2 2025, with the low at -$3.1 million in Q4 2024.
- The 5-year median for Other Non Operating Income is -$50000.0 (2025), against an average of -$126294.1.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income tumbled 666.67% in 2024, then jumped 2722.64% in 2025.
- Monte Rosa Therapeutics' Other Non Operating Income stood at -$283000.0 in 2022, then plunged by 175.27% to -$779000.0 in 2023, then plunged by 294.09% to -$3.1 million in 2024, then soared by 98.37% to -$50000.0 in 2025, then declined by 10.0% to -$55000.0 in 2026.
- Business Quant data shows GLUE's Other Non Operating Income at -$55000.0 in Q1 2026, -$50000.0 in Q4 2025, and -$29000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.42 Bn | 782.73 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54,000.00 |
| Mar 31, 2026 | -55,000.00 |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -29,000.00 |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | -48,000.00 |
| Dec 31, 2024 | -3.07 Mn |
| Sep 30, 2024 | -153,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 620,000.00 |
| Dec 31, 2023 | -779,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | -93,000.00 |
| Mar 31, 2023 | -85,000.00 |
| Dec 31, 2022 | -283,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 96,000.00 |
| Dec 31, 2021 | -66,000.00 |
| Sep 30, 2021 | 18,000.00 |